Yunpeng Yang1, Bin Wu2, Linian Huang3, Meiqi Shi4, Yunpeng Liu5, Yanqiu Zhao6, Lijun Wang7, Shun Lu8, Gongyan Chen9, Baolan Li10, Conghua Xie11, Jian Fang12, Nong Yang13, Yiping Zhang14, Jiuwei Cui15, Yong Song16, Cuiying Zhang17, Xiaodong Mei18, Bangwei Cao19, Lan Yang20, Ying Cheng21, Kejing Ying22, Tao Sun23, Biyong Ren24, Qitao Yu25, Zijun Liao26, Zhidong Pei27, Mengzhao Wang28, Jianying Zhou29, Shiying Yu30, Guosheng Feng31, Huiping Wan32, Huaqing Wang33, Shegan Gao34, Jinliang Wang35, Guangyu An36, Yi Geng37, Yanxia Ji38, Ying Yuan39, Shenglin Ma40, Zhongyao Jia41, Mu Hu42, Hui Zhou43, Jie Yu43, Xing Sun43, Li Zhang1. 1. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510000, China. 2. Department of Respiratory Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China. 3. Department of Respiratory Medicine, The First Affiliated Hospital of Bengbu Medical College, Bangbu 233000, China. 4. Department of Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China. 5. Department of Oncology, The First Hospital of China Medical University, Shenyang 110001, China. 6. Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou 450003, China. 7. Department of Tumor radiotherapy, The Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, China. 8. Department of Oncology, Shanghai Chest Hospital, Shanghai 200030, China. 9. Department of Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China. 10. General Department, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China. 11. Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. 12. Department of Oncology, Peking University Cancer Hospital, Beijing 100142, China. 13. Department of Pulmonary Gastroenterology, Hunan Cancer Hospital, Changsha 410006, China. 14. Department of Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China. 15. Department of Oncology, The First Hospital of Jilin University, Changchun 130000, China. 16. Department of Respiratory Medicine, General Hospital of Eastern Theater Command, Nanjing 210002, China. 17. Department of Oncology, Inner Mongolia People's Hospital, Hohhot 010017, China. 18. Department of Respiratory Medicine, An Hui Provincial Hospital, Hefei 230000, China. 19. Department of Oncology, Peking Friendship Hospital, Capital Medical University, Beijing 100050, China. 20. Department of Respiratory Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. 21. Department of Oncology, Jilin Cancer Hospital, Changchun 130000, China. 22. Department of Respiratory Medicine, Sir Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou 310016, China. 23. Department of Internal Medicine, Liaoning Cancer Hospital & Institute, Shenyang 110046, China. 24. Department of Respiratory Medicine, Chongqing three Gorges Central Hospital, Chongqing 404000, China. 25. Department of Oncology, The Cancer Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, China. 26. Department of Internal Medicine, Shaanxi Provincial Tumor Hospital, Xi'an 710061, China. 27. Department of Oncology, Luoyang Central Hospital Affiliated To Zhengzhou University, Luoyang 471009, China. 28. Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100005, China. 29. Department of Respiratory Medicine, The First Affiliated Hospital Zhejiang University, Hangzhou 310003, China. 30. Department of Oncology, Tongji Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China. 31. Department of Chemotherapy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, China. 32. Department of Oncology, Jiangxi People's Hospital, Nanchang 330000, China. 33. Department of Oncology, Tianjin People's Hospital, Tianjin 300121, China. 34. Department of Oncology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, China. 35. Department of Oncology, General Hospital of PLA, Beijing 100853, China. 36. Department of Oncology, Beijing Chao-Yang Hospital, Beijing 100020, China. 37. Department of Oncology, Baoji Central Hospital, Baoji 721008, China. 38. Department of Oncology, Handan Central Hospital, Handan 056001, China. 39. Department of Oncology, The Second Affiliated Hospital Zhejiang University, Hangzhou 310009, China. 40. Department of Oncology, Hangzhou First People's Hospital, Hangzhou 310002, China. 41. Department of Oncology, Linyi People's Hospital, Linyi 276003, China. 42. Department of Chest Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China. 43. Innovent Biologics, Inc., Suzhou 215123, China.
Abstract
BACKGROUND: Bevacizumab is a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF) and used for treatments of various cancers. Due to the high costs of bevacizumab treatments, a biosimilar provides an affordable alternative therapy for cancer patients. METHODS: In this randomized, double-blind, multicenter, phase 3 study, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor were enrolled and randomized (1:1) into IBI305 or bevacizumab groups. Patients received 6 cycles of paclitaxel/carboplatin plus IBI305 or bevacizumab 15 mg/kg intravenously followed by IBI305 or bevacizumab 7.5 mg/kg maintenance until disease progression, unacceptable toxicity or death. The primary endpoint was confirmed objective response rate (ORR) by an independent radiological review committee (IRRC) and secondary endpoints included disease control rate (DCR), progression-free survival (PFS), duration of response (DOR), overall survival (OS) and safety. RESULTS: A total of 450 NSCLC patients were enrolled (224 in IBI305 group and 226 in bevacizumab group). ORRs were 44.3% for IBI305 and 46.4% for bevacizumab, and the ORR ratio was 0.95 (90% CI: 0.803 to 1.135), within the predefined equivalence margin of 0.75 to 1.33. No significant difference in PFS (7.64 vs. 7.77 m, P=0.9987) was observed between the 2 groups. Serious adverse events (AEs) occurred in 33.5% (75/224) of patients in the IBI305 group and 37.6% (85/226) in the bevacizumab group. AEs ≥ grade 3 were similar in the IBI305 and bevacizumab groups [84.4% (189/224) vs. 89.8% (203/226), P=0.085]. CONCLUSIONS: IBI305 is similar to bevacizumab in terms of efficacy and safety. TRIAL REGISTRATION: Clinicaltrials.org Identifier: NCT02954172. Registered on 3 November 2016. Https://clinicaltrials.gov/. 2019 Translational Lung Cancer Research. All rights reserved.
BACKGROUND: Bevacizumab is a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF) and used for treatments of various cancers. Due to the high costs of bevacizumab treatments, a biosimilar provides an affordable alternative therapy for cancer patients. METHODS: In this randomized, double-blind, multicenter, phase 3 study, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor were enrolled and randomized (1:1) into IBI305 or bevacizumab groups. Patients received 6 cycles of paclitaxel/carboplatin plus IBI305 or bevacizumab 15 mg/kg intravenously followed by IBI305 or bevacizumab 7.5 mg/kg maintenance until disease progression, unacceptable toxicity or death. The primary endpoint was confirmed objective response rate (ORR) by an independent radiological review committee (IRRC) and secondary endpoints included disease control rate (DCR), progression-free survival (PFS), duration of response (DOR), overall survival (OS) and safety. RESULTS: A total of 450 NSCLC patients were enrolled (224 in IBI305 group and 226 in bevacizumab group). ORRs were 44.3% for IBI305 and 46.4% for bevacizumab, and the ORR ratio was 0.95 (90% CI: 0.803 to 1.135), within the predefined equivalence margin of 0.75 to 1.33. No significant difference in PFS (7.64 vs. 7.77 m, P=0.9987) was observed between the 2 groups. Serious adverse events (AEs) occurred in 33.5% (75/224) of patients in the IBI305 group and 37.6% (85/226) in the bevacizumab group. AEs ≥ grade 3 were similar in the IBI305 and bevacizumab groups [84.4% (189/224) vs. 89.8% (203/226), P=0.085]. CONCLUSIONS: IBI305 is similar to bevacizumab in terms of efficacy and safety. TRIAL REGISTRATION: Clinicaltrials.org Identifier: NCT02954172. Registered on 3 November 2016. Https://clinicaltrials.gov/. 2019 Translational Lung Cancer Research. All rights reserved.
Authors: Charles L Bennett; Brian Chen; Terhi Hermanson; Michael D Wyatt; Richard M Schulz; Peter Georgantopoulos; Samuel Kessler; Dennis W Raisch; Zaina P Qureshi; Z Kevin Lu; Bryan L Love; Virginia Noxon; Laura Bobolts; Melissa Armitage; John Bian; Paul Ray; Richard J Ablin; William J Hrushesky; Iain C Macdougall; Oliver Sartor; James O Armitage Journal: Lancet Oncol Date: 2014-11-24 Impact factor: 41.316
Authors: Tony S K Mok; Te-Chun Hsia; Chun-Ming Tsai; Kenneth Tsang; Gee-Chen Chang; John Wen-Cheng Chang; Thitiya Sirisinha; Sirisinha Thitiya; Virote Sriuranpong; Sumitra Thongprasert; Daniel T T Chua; Nicola Moore; Christian Manegold Journal: Asia Pac J Clin Oncol Date: 2011-06 Impact factor: 2.601
Authors: Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544
Authors: M Reck; J von Pawel; P Zatloukal; R Ramlau; V Gorbounova; V Hirsh; N Leighl; J Mezger; V Archer; N Moore; C Manegold Journal: Ann Oncol Date: 2010-02-11 Impact factor: 32.976
Authors: Mark A Socinski; Cornelius F Waller; Tazeen Idris; Igor Bondarenko; Alexander Luft; Katrin Beckmann; Ashwini Vishweswaramurthy; Subramanian Loganathan; Charles Donnelly; Matthew A Hummel; Roxann Shapiro; Melody Woods; Anita Rao; Vivek G Nayak; Gopinath Ranganna; Abhijit Barve Journal: Ther Adv Med Oncol Date: 2021-11-18 Impact factor: 8.168